Philadelphia-based Rothman Orthopaedic Institute has been at the forefront of spine care, and recently a team partnered with Thomas Jefferson University Hospita ...

Utilizing the Dural Substitute Confetti technique during spinal cord stimulation trial implantation may reduce complications and shorten surgery time.

A team of researchers led by Rice University's Jacob Robinson and the University of Texas Medical Branch's Peter Kan has ...

Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the ...

A key highlight of the quarter came right at the end when Nevro won FDA approval for HFX AdaptiveAI, an AI-powered, ...

HFX iQ is the first and only spinal cord stimulation (SCS) system integrating high-frequency SCS landmark ... The Senza HFX ...

The company announced receiving CE Mark Certification in Europe for its HFX iQ spinal cord stimulation system ... The Senza ...

The webcast will be held on November 26, 2024, at 2:00PM CET / 08:00AM ET. It will be hosted by CEO Dave Marver who will discuss highlights from Q3 2024 and provide a business update. To join the ...

Mississauga, Ontario--(Newsfile Corp. - November 11, 2024) - MyndTec Inc (CSE: MYTC). ("MyndTec" or the "Company"), a medical technology company focused on neurological treatment, rehabilitation and ...

The global spinal cord stimulators market is on a robust growth trajectory, poised to reach an impressive valuation of USD 5,441.4 million by 2033. Currently valued at USD 2,702.7 million in 2023, the ...

Suffering a spinal cord injury (SCI) in an accident is a life-altering event that comes with staggering financial ...

Data from the SENZA-PDN trial showed 10 kHz SCS yielded long-term, clinically meaningful reductions in HbA1c and weight in patients with PDN and T2D.